Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease

被引:0
|
作者
David Højland Ipsen
Jens Lykkesfeldt
Pernille Tveden-Nyborg
机构
[1] University of Copenhagen,Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences
来源
关键词
Lipid metabolism; Animal models; Pharmacotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) is currently the world’s most common liver disease, estimated to affect up to one-fourth of the population. Hallmarked by hepatic steatosis, NAFLD is associated with a multitude of detrimental effects and increased mortality. This narrative review investigates the molecular mechanisms of hepatic steatosis in NAFLD, focusing on the four major pathways contributing to lipid homeostasis in the liver. Hepatic steatosis is a consequence of lipid acquisition exceeding lipid disposal, i.e., the uptake of fatty acids and de novo lipogenesis surpassing fatty acid oxidation and export. In NAFLD, hepatic uptake and de novo lipogenesis are increased, while a compensatory enhancement of fatty acid oxidation is insufficient in normalizing lipid levels and may even promote cellular damage and disease progression by inducing oxidative stress, especially with compromised mitochondrial function and increased oxidation in peroxisomes and cytochromes. While lipid export initially increases, it plateaus and may even decrease with disease progression, sustaining the accumulation of lipids. Fueled by lipo-apoptosis, hepatic steatosis leads to systemic metabolic disarray that adversely affects multiple organs, placing abnormal lipid metabolism associated with NAFLD in close relation to many of the current life-style-related diseases.
引用
收藏
页码:3313 / 3327
页数:14
相关论文
共 50 条
  • [1] Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
    Ipsen, David Hojland
    Lykkesfeldt, Jens
    Tveden-Nyborg, Pernille
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2018, 75 (18) : 3313 - 3327
  • [2] Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease
    Yuki Kawano
    David E. Cohen
    [J]. Journal of Gastroenterology, 2013, 48 : 434 - 441
  • [3] Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease
    Kawano, Yuki
    Cohen, David E.
    [J]. JOURNAL OF GASTROENTEROLOGY, 2013, 48 (04) : 434 - 441
  • [4] Hepatic lipid metabolism and non-alcoholic fatty liver disease
    Tessari, P.
    Coracina, A.
    Cosma, A.
    Tiengo, A.
    [J]. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2009, 19 (04) : 291 - 302
  • [5] How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
    Yana Geng
    Klaas Nico Faber
    Vincent E. de Meijer
    Hans Blokzijl
    Han Moshage
    [J]. Hepatology International, 2021, 15 : 21 - 35
  • [6] How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
    Geng, Yana
    Faber, Klaas Nico
    de Meijer, Vincent E.
    Blokzijl, Hans
    Moshage, Han
    [J]. HEPATOLOGY INTERNATIONAL, 2021, 15 (01) : 21 - 35
  • [7] Beneficial mechanisms of aerobic exercise on hepatic lipid metabolism in non-alcoholic fatty liver disease
    Rui Guo
    Emily C Liong
    Kwok Fai So
    Man-Lung Fung
    George L Tipoe
    [J]. Hepatobiliary & Pancreatic Diseases International, 2015, 14 (02) : 139 - 144
  • [8] Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging
    Gong, Zhenwei
    Tas, Emir
    Yakar, Shoshana
    Muzumdar, Radhika
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2017, 455 (0C) : 115 - 130
  • [9] Beneficial mechanisms of aerobic exercise on hepatic lipid metabolism in non-alcoholic fatty liver disease
    Guo, Rui
    Liong, Emily C.
    So, Kwok Fai
    Fung, Man-Lung
    Tipoe, George L.
    [J]. HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2015, 14 (02) : 139 - 144
  • [10] Non-alcoholic fatty liver disease associated molecular mechanisms of hepatocarcinogenesis
    Li, Bei
    Lu, Jiong
    You, Zhen
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2021, 14 (04): : 1559 - 1568